Catalyst Pharmaceuticals Buys Exclusive North American License For Vamorolone For Duchenne Muscular Dystrophy From Santhera
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals has acquired an exclusive North American license for Vamorolone, a treatment for Duchenne Muscular Dystrophy, from Santhera. The license includes exclusive commercial rights in the U.S., Canada, and Mexico, and the right of first negotiation in Europe and Japan. Catalyst has paid $75 million in cash for the license.
July 19, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals has made a significant investment in acquiring the North American license for Vamorolone. This could potentially open up new revenue streams for the company.
Catalyst Pharmaceuticals' acquisition of the Vamorolone license represents a significant investment by the company. This could potentially lead to new revenue streams if the treatment is successful and approved for use. Therefore, this news is highly relevant and important for investors in Catalyst Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100